重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 196,838股。 本次股票上市流通总数为196,838股。 本次股票上市流通日期为2025 年 10 月 27 日。 | 证券代码：603939 | 证券简称：益丰药房 | 公告编号：2025-100 | | --- | --- | --- | | 债券代码：113682 | 债券简称：益丰转债 | | 益丰大药房连锁股份有限公司 关于 2022 年限制性股票激励计划预留授予股份 第二次解除限售暨上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 于公司<2022 年限制性股票激励计划（草案）>及摘要的议案》、《关于公司<2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请公司股东大会 授权董事会办理限制性股票激励计划相关事宜的议案》，并披露了《关于 2022 年 限制性股票激励计划内幕信息知情人的自查报告》。 4、2024 年 10 月 14 日，公司召开的第五届董事会第八次会议与第五届监事会 第六次会议审议通过了《 ...

湖南启元律师事务所 关于益丰大药房连锁股份有限公司 2022年限制性股票激励计划预留授予股份第 二次解除限售暨上市相关事项的 法律意见书 $$\Xi{\cal{O}}{\underline{{{-\mp\hbar\mp}}}}+\Xi$$ 致：益丰大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）受益丰大药房连锁股份有限公司 （以下简称"益丰药房"或"公司"）委托，担任公司实施 2022 年限制性股票激 励计划项目专项法律顾问，根据《上市公司股权激励管理办法》（以下简称"《管 理办法》"）、《益丰大药房连锁股份有限公司章程》（以下简称"《公司章程》"）、 《益丰大药房连锁股份有限公司 2022 年限制性股票激励计划（修订版）》（以下 简称"《激励计划》"）等有关规定，就公司 2022 年限制性股票激励计划预留授 予股份第二次解除限售暨上市（以下简称"本次解除限售并上市"）相关事项出 具本法律意见书。 本所仅就与本次解除限售及本次回购注销有关的中华人民共和国境内（以下 简称"中国境内"，为本法律意见书之目的，不包括香港特别行政区、澳门特别 行政区和台湾地区）法律问题发表法律意见，而不对有关会计、审计 ...

Market Overview - The pharmaceutical commercial sector increased by 0.55% on October 21, with First Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Stock Performance - First Pharmaceutical (600833) closed at 13.64, up 2.48% with a trading volume of 58,500 shares and a transaction value of 79.03 million yuan [1] - Other notable performers included: - Haiwang Biological (000078) at 2.55, up 2.41% [1] - HeFu China (603122) at 6.55, up 2.34% [1] - Ruikang Pharmaceutical (002589) at 2.93, up 2.09% [1] - Daclin (603233) at 18.67, up 1.52% with a transaction value of 293 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 105 million yuan from institutional investors and 110 million yuan from speculative funds, while retail investors saw a net inflow of 215 million yuan [2] - The capital flow for individual stocks showed mixed results, with China Pharmaceutical (600056) seeing a net inflow of 28.32 million yuan from institutional investors [3] Individual Stock Capital Flow - Key stocks with significant capital flow include: - China Pharmaceutical (600056) with a net inflow of 28.32 million yuan from institutional investors [3] - Jiuzhoutong (600998) with a net inflow of 24.77 million yuan from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 11.37 million yuan from institutional investors [3]

Core Viewpoint - Yifeng Pharmacy is focusing on integrating online and offline operations through CRM and big data, aiming to innovate in internet healthcare and prescription circulation [1] Group 1: Business Strategy - The company has established over 10,000 direct-operated stores as part of its O2O strategy [1] - Yifeng Pharmacy has developed a shopping platform via mini-programs and an official e-commerce flagship store [1] - A comprehensive logistics service system has been created, including provincial warehouses, city center warehouses, and hospital-side stores to enhance fulfillment capabilities [1] Group 2: Market Positioning - The company is building a complete B2C, O2O, and third-party logistics system to improve service delivery [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.77% on October 17, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed mixed performance, with Jianfa Zhixin rising by 4.20% to a closing price of 28.05, while Baiyang Pharmaceutical fell by 3.09% to 25.75 [1][2] - Other notable performers included Yifeng Pharmacy (+1.19%), Dacilin (+1.10%), and Dajia Weikang (+0.35%) [1][2] Trading Volume and Value - Jianfa Zhixin had a trading volume of 194,100 shares and a transaction value of 547.1 million yuan, while Baiyang Pharmaceutical had a trading volume of 33,700 shares and a transaction value of 118.76 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 246 million yuan from institutional investors, while retail investors contributed a net inflow of 220 million yuan [2][3] - Notable capital flows included Jianfa Zhixin with a net inflow of 44.84 million yuan from institutional investors, while Baiyang Pharmaceutical experienced a net outflow of 964,800 yuan [3]

Core Viewpoint - The pharmaceutical commercial sector experienced a decline of 0.27% on October 16, with Saily Medical leading the drop. The Shanghai Composite Index rose by 0.1%, while the Shenzhen Component Index fell by 0.25 [1][2]. Group 1: Market Performance - The pharmaceutical commercial sector's stocks showed mixed performance, with notable gainers including: - Jianfa Zhixin (301584) at 26.92, up 1.24% with a trading volume of 97,100 shares and a turnover of 262 million yuan - Yifeng Pharmacy (603939) at 24.41, up 1.12% with a trading volume of 75,400 shares and a turnover of 184 million yuan - Daclin (603233) at 17.31, up 1.11% with a trading volume of 96,800 shares and a turnover of 169 million yuan [1]. - Conversely, Saily Medical (603716) saw a significant decline of 3.65%, closing at 25.88 with a trading volume of 256,800 shares [2]. Group 2: Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 243 million yuan from institutional investors, while retail investors saw a net inflow of 210 million yuan [2][3]. - Notable capital flows for specific stocks included: - Jianfa Zhixin (301584) with a net inflow of 15.55 million yuan from institutional investors, but a net outflow of 13.82 million yuan from retail investors [3]. - Baiyang Pharmaceutical (301015) had a net inflow of 10.41 million yuan from institutional investors, while retail investors experienced a net outflow of 11.76 million yuan [3].

Core Viewpoint - The Shanghai Composite Index closed at 3916.23 points, above the annual line, with a slight increase of 0.10% on the day, and the total trading volume of A-shares reached 1,948.66 billion yuan [1][2] Group 1: Market Performance - As of the latest close, 19 A-shares have surpassed the annual line, indicating positive market sentiment [1] - The stocks with the largest deviation rates include Shenglong Co., Changshan Beiming, and Youlide, with deviation rates of 9.96%, 3.76%, and 2.52% respectively [1] - The total trading volume for A-shares today was 1,948.66 billion yuan, reflecting active market participation [1] Group 2: Individual Stock Highlights - Shenglong Co. (603178) saw a daily increase of 10.00% with a turnover rate of 9.13% and a latest price of 21.45 yuan, resulting in a deviation rate of 9.96% [1] - Changshan Beiming (000158) increased by 9.98% with a turnover rate of 9.68%, latest price at 24.57 yuan, and a deviation rate of 3.76% [1] - Youlide (688628) experienced a 4.23% increase, with a turnover rate of 2.91%, latest price of 36.22 yuan, and a deviation rate of 2.52% [1]

Market Overview - The Shanghai Composite Index is at 3916.86 points, above the annual line, with a change of 0.12% [1] - The total trading volume of A-shares is 909.4 billion yuan [1] Stocks Breaking Annual Line - A total of 20 A-shares have surpassed the annual line today, with notable stocks including: - Shenglong Co., Ltd. (603178) with a deviation rate of 9.96% - Lege Co., Ltd. (300729) with a deviation rate of 2.14% - Jinguang Co., Ltd. (300510) with a deviation rate of 1.75% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates after breaking the annual line: - Shenglong Co., Ltd. (603178): Today's change of 10.00%, turnover rate of 4.72%, latest price at 21.45 yuan [1] - Lege Co., Ltd. (300729): Today's change of 4.01%, turnover rate of 4.10%, latest price at 15.58 yuan [1] - Jinguang Co., Ltd. (300510): Today's change of 2.00%, turnover rate of 5.62%, latest price at 4.60 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Changjiang Electric Power (600900): Today's change of 0.36%, latest price at 28.03 yuan, deviation rate of 0.01% [2] - Beiqi Blue Valley (600733): Today's change of 3.05%, latest price at 8.11 yuan, deviation rate of 0.03% [2] - Hongcheng Environment (600461): Today's change of 0.22%, latest price at 9.10 yuan, deviation rate of 0.05% [2]

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds, despite triggering the price adjustment clause due to stock prices being below 85% of the current conversion price for a specified period [2][6]. Group 1: Convertible Bond Overview - The company issued 17,974,320 convertible bonds with a total value of 1,797.432 million yuan, with a maturity of six years and a tiered interest rate starting from 0.30% in the first year [3]. - The initial conversion price was set at 39.85 yuan per share, which has been adjusted multiple times due to equity distribution plans, with the latest adjustment bringing it to 31.84 yuan per share [3][5]. Group 2: Price Adjustment Clause - The price adjustment clause allows for a downward revision of the conversion price if the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [4][5]. - The company has triggered this clause but has opted not to implement a downward adjustment at this time, citing confidence in its long-term value and the need to protect investor interests [6]. Group 3: Future Considerations - The company will not propose a downward adjustment for the next three months, and any future triggers for price adjustment will be reassessed starting January 16, 2026 [2][6].

Core Viewpoint - Yifeng Pharmacy announced that it will not lower the conversion price of its "Yifeng Convertible Bonds" during the upcoming three-month period, even if the stock price triggers the adjustment clause [1] Summary by Sections Company Decision - The company held its 23rd meeting of the fifth board of directors on October 15, 2025, where it approved the proposal not to lower the conversion price of the "Yifeng Convertible Bonds" [1] - The decision means that from October 16, 2025, to January 15, 2026, the conversion price will remain unchanged, regardless of stock price movements [1] Future Considerations - The next period for triggering the conversion price adjustment clause will start from January 16, 2026 [1] - If the stock price triggers the adjustment clause again, the board will convene to decide whether to exercise the right to lower the conversion price [1]